Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Publication | Open Access

DOI Full Paper Access

130

Citations

References

2020

Year

Miguel Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, Eva Carrasco, Nicholas C. Turner, Eva Ciruelos, Begoña Bermejo, A. Antón, Zsuzsanna Kahán, Tibor Csőszi,

Annals of Oncology